Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Cavco Industries
CVCO
$4.58B
| $19.2M | 0.01% |
80,995
+2,778
| +4% | +$668K |
|
|
RETA
1627
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $19.2M | 0.01% |
190,564
+4,929
| +3% | +$578K |
|
1628
Trupanion
TRUP
$1.34B
| $19.2M | 0.01% |
246,621
+4,676
| +2% | +$461K |
|
1629
Pacira BioSciences
PCRX
$929M
| $19.1M | 0.01% |
341,060
+19,642
| +6% | +$1.13M |
|
1630
Cardlytics
CDLX
$24.8M
| $19.1M | 0.01% |
22,750
+225
| +1% | +$228K |
|
1631
Sonic Automotive
SAH
$2.53B
| $19.1M | 0.01% |
362,626
+11,094
| +3% | +$562K |
|
|
ITCI
1632
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $19M | 0.01% |
509,500
+18,487
| +4% | +$643K |
|
|
VGR
1633
DELISTED
Vector Group Ltd.
VGR
| $19M | 0.01% |
2,098,310
+93,242
| +5% | +$909K |
|
1634
Hilltop Holdings
HTH
$2.27B
| $19M | 0.01% |
580,698
-1,267
| -0.2% | -$42K |
|
1635
Doximity
DOCS
$4.49B
| $19M | 0.01% |
+235,021
| New | +$17.2M |
|
1636
First Merchants
FRME
$2.72B
| $19M | 0.01% |
453,097
+3,635
| +0.8% | +$148K |
|
1637
Agios Pharmaceuticals
AGIO
$2.02B
| $18.9M | 0.01% |
410,601
+35,095
| +9% | +$1.7M |
|
|
RAVN
1638
DELISTED
Raven Industries Inc
RAVN
| $18.9M | 0.01% |
328,857
-6,665
| -2% | -$386K |
|
1639
Enterprise Products Partners
EPD
$82.1B
| $18.9M | 0.01% |
875,410
+53,218
| +6% | +$1.21M |
|
1640
PRA Group
PRAA
$775M
| $18.9M | 0.01% |
448,737
+17,276
| +4% | +$689K |
|
1641
Ironwood Pharmaceuticals
IRWD
$682M
| $18.8M | 0.01% |
1,440,085
+258,897
| +22% | +$3.35M |
|
1642
Bloom Energy
BE
$72.5B
| $18.8M | 0.01% |
1,003,492
+80,997
| +9% | +$1.71M |
|
|
CSR
1643
Centerspace
CSR
$935M
| $18.8M | 0.01% |
198,698
+17,175
| +9% | +$1.62M |
|
1644
Adeia
ADEA
$3.14B
| $18.8M | 0.01% |
3,765,201
-289,582
| -7% | -$1.56M |
|
|
ODP
1645
DELISTED
ODP
ODP
| $18.7M | 0.01% |
466,506
-47,141
| -9% | -$2.12M |
|
|
KRTX
1646
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $18.7M | 0.01% |
152,873
+15,657
| +11% | +$1.81M |
|
|
MGLN
1647
DELISTED
Magellan Health Services, Inc.
MGLN
| $18.7M | 0.01% |
197,748
+2,967
| +2% | +$281K |
|
1648
G-III Apparel Group
GIII
$1.43B
| $18.7M | 0.01% |
659,937
-75,901
| -10% | -$2.29M |
|
1649
Coinbase
COIN
$39.3B
| $18.6M | 0.01% |
81,966
+15,920
| +24% | +$3.92M |
|
|
HSKA
1650
DELISTED
Heska Corp
HSKA
| $18.6M | 0.01% |
72,019
+4,336
| +6% | +$1.11M |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.